Stabilization of SETD2 with Palmostatin-B, a drug the prevents de-palmitoylation, led to decreased proliferation of established GBM cell lines and decreased tumor growth in a nude mouse model, consistent with an antiproliferative role for SETD2 in GBM (172). This evidence concerns the gene SETD2 and glioblastoma.